Gadoteric acid meglumine contrast agent

Published Last updated See all updates

SPS PGD template for administering gadoteric acid meglumine intravenously for imaging investigations and procedures by registered Radiographers.

Provenance

Created by SPS, NHS England, the Royal College of Radiologists (RCR) and the Society of Radiographers (SoR), with the support of specialists working within clinical practice, for contrast agents commonly used in NHS England-commissioned radiology services.

PGD template attachment

This attached template covers the following gadoteric acid meglumine contrast agents:

  • Dotarem®
  • Clariscan®
  • Dotagraf®
  • Cyclolux®

Download and use in conjunction with our implementation advice.

Version 3.0 published

Version 3.0 of this PGD template has been published and is valid for use from April 2025. It has been published in advance of its valid from date to allow organisations time to take it through local governance processes.

Version 2.0 remains valid until the end of March 2025 – it will be removed from this webpage on expiry.

More radiology PGD templates

All PGD templates

Templates

National PGD templates are developed with experts for clinical specialties. They reduce duplication and variation, and improve consistency of care.

Update history

  1. V3 published
  1. Title, URL and summary amended.
  1. Temporary detail on expiry of V1.0 removed
  1. V2.1 uploaded (rewording of adverse effects section)
  1. Updated PGD template V2.0 added
  1. Published

Print this page

admin